In April, NaviFUS entered into a cooperation agreement with Bracco, a global leader in ultrasound imaging agents, to enhance the NaviFUS® System’s capability to open the blood-brain barrier (BBB) for the treatment of brain cancers and neurological diseases. This year, the system will be tested in several clinical trials, marking a significant advancement in non-invasive therapies.
NaviFUS (6872) and Bracco, the world’s leading brand of ultrasound imaging agents, officially signed a cooperation agreement recently (4/26). Bracco will provide its microbubble imaging agents as part of the NaviFUS system’s treatment to open the blood-brain barrier (BBB). As a technology platform, the NaviFUS System will be used in clinical trials of various brain cancers or neurological diseases and registrations for the treatment. It is expected that after obtaining the marketing authorization, Bracco will be responsible for supplying this microbubble OEM product and authorize NaviFUS to bundle it as a medical device consumable with its device for acoustic therapy sales.
“Queen of Tears,” a recent popular Netflix K-Drama has been captivating global audiences with the tumultuous romance between its two main leads. It also happens to feature a look into some real innovative medical advancements in the treatment of brain tumors. The focused ultrasound treatment Hong Hae-in (Kim Ji-won) receives for her glioblastoma has been utilized in Taiwanese medtech firm NaviFUS’ clinical trials for the last few years and highlights Taiwan’s role as a leader in focused ultrasound advancements for the treatment of brain cancer.
Key Points:
– A new clinical trial is investigating sonodynamic therapy for patients with recurrent glioblastoma.
– This is the first clinical trial in the US to use the NaviFUS device, which combines neuronavigation with a mobile, noninvasive focused ultrasound system.
NaviFUS Corporation is excited to announce that it recently received approval by the United States Food and Drug Administration (FDA) for an investigational device exemption (IDE) clinical trial using its NaviFUS® System focused ultrasound (FUS) device. The pilot-early feasibility study will be conducted at University of Virginia and will evaluate the combined effect of using the NaviFUS System® to open the blood-brain-barrier (BBB) and bevacizumab (Avastin®) drug treatment in rGBM patients.
